A 4-year-old boy from Delhi presents with intense pruritus and excoriated lesions over the antecubital and popliteal fossae, wrists, and neck for the past 18 months. His mother reports that symptoms worsen in winter and improve slightly in summer. On examination, he has lichenification, xerosis, and a positive Dennie–Morgan fold. Serum IgE is elevated at 850 IU/mL. His father has a history of allergic rhinitis. Which of the following is the MOST appropriate first-line pharmacological management for acute flares?

Explanation

## Diagnosis & Clinical Context **Key Point:** This is a classic presentation of **atopic dermatitis (AD)** in a child, evidenced by: - Age of onset (typically 2–5 years) - Characteristic distribution (flexural surfaces) - Intense pruritus with lichenification and xerosis - Dennie–Morgan fold (a hallmark sign) - Elevated serum IgE - Family history of atopy (father's allergic rhinitis) - Seasonal variation (worse in winter when humidity is low) ## First-Line Management Algorithm ```mermaid flowchart TD A[Atopic Dermatitis Flare]:::outcome --> B{Severity?}:::decision B -->|Mild to Moderate| C[Emollients + Topical Corticosteroid]:::action B -->|Severe/Widespread| D[Systemic Corticosteroid Short Course]:::action C --> E[Hydrocortisone 1% or Triamcinolone 0.1%]:::action D --> F[Prednisolone 0.5-1 mg/kg/day × 1-2 weeks]:::action E --> G[Twice daily + emollients]:::action F --> G G --> H[Review in 1-2 weeks]:::outcome ``` ## Why Topical Corticosteroid Is Correct **High-Yield:** For **mild-to-moderate acute flares** in children, the evidence-based first-line approach is: 1. **Emollients** (moisturizers) — foundation of all AD management 2. **Topical corticosteroid** — rapid anti-inflammatory effect - Hydrocortisone 1% (Class VII, safest for face/neck/intertriginous areas) - Triamcinolone 0.1% (Class IV, for body) - Apply twice daily for 1–2 weeks, then taper **Clinical Pearl:** Topical corticosteroids are the gold standard for localized AD because they: - Act within 24–48 hours - Minimize systemic absorption (especially with hydrocortisone) - Are safe for long-term use in children when used correctly - Reduce pruritus and allow skin barrier repair **Key Point:** Emollients must accompany topical steroids — they repair the impaired skin barrier (defective filaggrin, ceramide loss) that is fundamental to AD pathogenesis. ## Steroid Potency & Pediatric Safety | Potency Class | Agent | Pediatric Use | Notes | |---|---|---|---| | VII (Weakest) | Hydrocortisone 1% | Safe, face/neck | First-line for mild AD | | IV | Triamcinolone 0.1% | Safe, short-term | Body/trunk | | II–III | Clobetasol, Betamethasone | Avoid in children | Risk of atrophy, HPA axis suppression | **Mnemonic: STEP-UP** — **S**teroids (topical first), **T**acrolimus (if steroid-sparing needed), **E**mollients (always), **P**hototherapy (severe), **U**pdate with systemic agents (last resort), **P**robiotic/allergen avoidance (adjunctive). ## Why This Child Does NOT Need Systemic Corticosteroids Yet Although his AD is chronic and moderately severe (lichenification, widespread), the lesions are: - Localized to flexural areas (not generalized) - Responsive to seasonal factors (suggesting environmental control is possible) - Not described as acute, severe, or unresponsive to topical therapy Systemic corticosteroids (prednisolone) are reserved for: - Severe, acute flares with widespread involvement - Failure of topical therapy after 2–4 weeks - Risk of rebound flare upon discontinuation [cite:Irvine et al. (AAD/AADA Guidelines) 2016; Sharma et al. (IADVL) 2019]